23:48 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Thrombosis In vitro, cell culture and mouse studies identified a choline-based inhibitor of bacterial cutC that could help treat thrombosis. Chemical synthesis of choline analogs, and in vitro and bacterial cell-based enzymatic activity assays...
20:38 , Aug 6, 2018 |  BC Extra  |  Preclinical News

Modifying microbes for clot prevention

Cleveland Clinic researchers have developed inhibitors of bacterial choline trimethylamine-lyase (bacterial cutC), an enzyme found in commensal gut microbes, that could help treat thrombosis by targeting bacterial metabolic activity without killing the microbes. Previous studies identified...
18:22 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Candida HEK cells engineered to synthesize and secrete bacterial AI-2 could help treat candidiasis. The cells are generated by transfecting HEK cells with two constructs: a sensor unit, based on formyl peptide receptor 1 (FPR1),...
18:57 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro, cell culture and mouse studies suggest inhibiting the DNAJ/Hsp70 chaperone axis could help treat castration-resistant prostate cancer (CRPC). Screening of a library of chalcone analogs and testing in cell-based signaling assays...
18:34 , May 25, 2018 |  BC Week In Review  |  Clinical News

FDA approves BioMarin's phenylketonuria drug

FDA approved Palynziq pegvaliase-pqpz from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to treat phenylketonuria (PKU) in patients who have uncontrolled blood phenylalanine levels on current treatment. The company expects to launch the drug by the end of June....
15:29 , May 25, 2018 |  BC Week In Review  |  Clinical News

Esperion's hypercholesterolemia candidate meets in Phase III

Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily 180 mg oral bempedoic acid (ETC-1002) met the primary endpoint of reducing LDL-C from baseline to week 12 vs. placebo (23% vs. 1%, p<0.001) in the Phase III CLEAR...
23:05 , May 24, 2018 |  BC Extra  |  Company News

FDA approves BioMarin's phenylketonuria drug

FDA approved Palynziq pegvaliase-pqpz from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to treat phenylketonuria (PKU) in patients who have uncontrolled blood phenylalanine levels on current treatment. The company expects to launch the drug by the end of June....
16:09 , May 4, 2018 |  BC Week In Review  |  Clinical News

Esperion reports Phase III data for hypercholesterolemia candidate

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) met the primary safety endpoint and key secondary efficacy endpoint in the Phase III CLEAR Harmony (1002-040) trial to treat high-risk atherosclerotic cardiovascular disease (ASCVD) patients with...
16:51 , May 2, 2018 |  BC Extra  |  Clinical News

Esperion falls on Phase III data for hypercholesterolemia candidate

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) met the primary safety endpoint and key secondary efficacy endpoint in the Phase III CLEAR Harmony (1002-040) trial to treat high-risk atherosclerotic cardiovascular disease (ASCVD) patients with...
19:52 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

BioMarin announces gene therapy candidate for PKU

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said in its 1Q18 earnings report that it plans to submit an IND next year for a gene therapy candidate to treat phenylketonuria (PKU). The candidate will be an adeno-associated virus (AAV)...